Genetic vaccines - SAVIMS

COVID-19, Covid-19 vaccines, Genetic vaccines, Peer-reviewed evidence, Resource Type, Vaccine safety & adverse events, Vaccines, Viral illnesses

Evaluation of COVID-19 Vaccine Safety Profile

Director | 01/01/2021 | COVID-19, Covid-19 vaccines, Genetic vaccines, Peer-reviewed evidence, Resource Type, Vaccine safety & adverse events, Vaccines, Viral illnesses

Reference: Wu, Q., Dudley, M. Z., Chen, X., Bai, X., Dong, K., Zhuang, T., Salmon, D., & Yu, H. (2021). Evaluation of the safety profile of COVID-19 vaccines: a rapid review. BMC Medicine, 19, 173. https://doi.org/10.1186/s12916-021-02059-5 Summary: This article presents a rapid review and meta-analysis of the safety profiles of COVID-19 vaccines. It highlights public […]

Genetic vaccines, Other viral illnesses, Peer-reviewed evidence, Resource Type, Vaccine effectiveness, Vaccines, Viral illnesses

The Evolution of mRNA Vaccines

Director | 12/01/2018 | Genetic vaccines, Other viral illnesses, Peer-reviewed evidence, Resource Type, Vaccine effectiveness, Vaccines, Viral illnesses

Reference: Pardi, N., Hogan, M. J., Porter, F. W., & Weissman, D. (2018). mRNA vaccines — a new era in vaccinology. Nature Reviews Drug Discovery, 17(4), 261-279. https://doi.org/10.1038/nrd.2017.243 Summary: mRNA vaccines offer a potent alternative to traditional vaccine approaches due to their rapid development and cost-effective manufacturing. They have shown promise in preventing infectious diseases

Genetic vaccines, Other viral illnesses, Peer-reviewed evidence, Resource Type, Vaccine effectiveness, Vaccines, Viral illnesses

Immunogenicity of mRNA Vaccines for Influenza Viruses

Director | 24/03/2017 | Genetic vaccines, Other viral illnesses, Peer-reviewed evidence, Resource Type, Vaccine effectiveness, Vaccines, Viral illnesses

Reference: Bahl, K., Senn, J. J., Yuzhakov, O., Bulychev, A., Brito, L. A., Hassett, K. J., Laska, M. E., Smith, M., Almarsson, Ö., Thompson, J., Ribeiro, A. (Mick), Watson, M., Zaks, T., & Ciaramella, G. (2017). Preclinical and clinical demonstration of immunogenicity by mRNA vaccines against H10N8 and H7N9 influenza viruses. Molecular Therapy, 25(6), 1316-1326.